No Data
RBC Capital Maintains IGM Biosciences(IGMS.US) With Buy Rating, Maintains Target Price $20
Shareholders May Find It Hard To Justify Increasing IGM Biosciences, Inc.'s (NASDAQ:IGMS) CEO Compensation For Now
Will IGM Biosciences (NASDAQ:IGMS) Spend Its Cash Wisely?
IGM Biosciences to Present at the Jefferies Healthcare Conference
In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Maintains Target Price $12